EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Precision Transformation of Meningioma Diagnosis and Treatment: Advances in Molecular Pathology and Systemic Therapy

Wenlin Chen, Yinzi Wu, Ruxu Geng, Yuhe Wang, Zhiqin Xu, Yi Yang, Wenbin Ma, Yu Wang, Yuanli Zhao, Xinjie Bao

Current Oncology · 09.11.2026 · 33 (11) · 692

DOI: 10.3390/curroncol33110692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 09.11.2026. Verfasst von Wenlin Chen und 9 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningiomas are the most common primary intracranial tumors of the central nervous system. They exhibit highly heterogeneous biological behavior that current histological grading cannot reliably predict. Currently, there are no standardized systemic treatment regimens for recurrent or refractory meningiomas; therefore, molecular subtyping is crucial for assessing prognosis and guiding treatment decisions. Key alterations, including NF2, TERT promoter, CDKN2A/B, AKT1, and SMO, contribute to the proliferation, invasion, and recurrence of meningiomas. This review summarizes the advances in molecular pathological alterations and clinical studies on systemic therapy for meningiomas. Anti-angiogenic agents, immune checkpoint inhibitors, and inhibitors targeting multiple signaling pathways represent promising directions. Anti-angiogenic therapy has demonstrated disease control, whereas PD-1 inhibitors have shown limited benefit in unstratified populations but may be of value in specific molecular subgroups. Molecularly stratified umbrella and basket trials are advancing precision treatment, and peptide receptor radionuclide therapy provides benefit for patients with specific molecular alterations. Some early trials of targeted therapies and immunotherapies have shown positive signals, but the overall level of evidence remains limited. Future studies should employ more rigorous trial designs and encourage patient participation to clarify the clinical value of each strategy and drive the shift from empirical to molecularly guided treatment.

Förderung

  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Chen, W., Wu, Y., Geng, R., Wang, Y., Xu, Z., Yang, Y., Ma, W., Wang, Y., Zhao, Y., & Bao, X. (2026). Precision Transformation of Meningioma Diagnosis and Treatment: Advances in Molecular Pathology and Systemic Therapy. Current Oncology, 33(11), 692. https://doi.org/10.3390/curroncol33110692

Vancouver

Chen W, Wu Y, Geng R, Wang Y, Xu Z, Yang Y, et al. Precision Transformation of Meningioma Diagnosis and Treatment: Advances in Molecular Pathology and Systemic Therapy. Current Oncology. 2026;33(11):692. doi:10.3390/curroncol33110692

BibTeX
@article{Chen2026,
  author = {Chen, Wenlin and Wu, Yinzi and Geng, Ruxu and Wang, Yuhe and Xu, Zhiqin and Yang, Yi and Ma, Wenbin and Wang, Yu and Zhao, Yuanli and Bao, Xinjie},
  title = {Precision Transformation of Meningioma Diagnosis and Treatment: Advances in Molecular Pathology and Systemic Therapy},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {11},
  pages = {692},
  doi = {10.3390/curroncol33110692}
}
Kostenlos starten →